Terminated trial sought new hope for tough cancer
NCT ID NCT04166734
Summary
This early-stage study tested whether combining a targeted, high-dose radiation (SBRT) with an immunotherapy drug (pembrolizumab) was safe and effective for patients with advanced, inoperable pleural mesothelioma whose cancer had progressed after initial chemotherapy. The trial was designed to first check safety in a small group before expanding, but it was terminated early. It aimed to see if this combination could better control the cancer and extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Royal Marsden NHS Foundation Trust
Chelsea, United Kingdom
Conditions
Explore the condition pages connected to this study.